Skip to main content Back to Top
Advertisement

5/26/2016

Labetalol Injection

Reason for the Shortage

    • Hospira had labetalol on shortage due to increased demand.
    • Sagent suspended production on labetalol 5 mg/mL 20 mL vials (NDC 25021-0300-20) in July 2013 and 40 mL vials in February 2014 (NDC 25021-0300-40) and the company has no estimated release date for further production.
    • West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including labetalol injection. West-Ward is not actively marketing labetalol injection.

Available Products

    • Labetalol injection, Akorn, 5 mg/mL, 20 mL vial, 1 count, NDC 17478-0420-20
    • Labetalol injection, Akorn, 5 mg/mL, 40 mL vial, 1 count, NDC 17478-0420-40
    • Labetalol injection, Pfizer, 5 mg/mL, 20 mL vial, 1 count, NDC 00409-2267-20
    • Labetalol injection, Pfizer, 5 mg/mL, 4 mL Carpuject syringe, 10 count, NDC 00409-2339-34
    • Labetalol injection, Pfizer, 5 mg/mL, 40 mL vial, 1 count, NDC 00409-2267-54

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 21, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.